June 10, 2025

SAN FRANCISCO, CA — GenLab, the venture studio that builds AI-native companies for innovative corporations, next-generation infrastructure and national resilience, today announced a strategic investment in Lymbic AI, the neurotechnology startup pioneering brainwave-based biometric security. This partnership reflects GenLab’s growing focus on identity integrity, autonomy, and resistance to synthetic fraud across both public and private systems.

GenLab Founder Daniel Riedel previously testified before the U.S. Senate on cyber defense for critical infrastructure, highlighting the urgent need for persistent, high-integrity identity in digital systems—a challenge Lymbic directly addresses.

Lymbic AI’s flagship product, Neuroprint, leverages EEG signals—unique electrical patterns generated by the brain—as a privacy-preserving biometric. By analyzing ten consecutive one-second EEG samples, Neuroprint continuously confirms identity without any physical contact, making it inherently resistant to spoofing or deepfake attacks. This approach is especially valuable in defense, finance, and healthcare environments where system integrity and human presence must be indisputable.

With Neuroprint, the threshold for granting access is configurable: most deployments use an authentication accuracy north of 99.9%. For ultra–high-security applications, the system can be set to demand even greater accuracy.

“As AI systems become more powerful, identity becomes the last line of defense. Neuroprint doesn’t just authenticate users—it builds a persistent trust fabric that resists deepfakes, spoofing, and coercion. That’s the kind of foundational capability GenLab is here to back.”- Daniel Riedel, Managing Partner/CEO of GenLab Venture Studio 

“Passwords are broken, and traditional biometrics like face and voice are no longer safe in the age of deepfakes,” said Nikolaus Wischmann, CEO and Co-Founder of Lymbic AI. “Our collaboration with GenLab accelerates our mission to build trust in digital systems by grounding security in the one thing that can’t be forged—our own brain.”

“Neuroprint isn’t just another authentication tool—it’s a new protocol for trust,” added Nathaniel Rose, Lymbic’s Co-Founder and CTO. “By layering temporal brain signals with deep learning and offering a flexible threshold, we’ve created a system where false positives collapse under statistical rigor, and user convenience can be optimized on the fly.”

Lymbic AI has already signed pilot agreements with private and public-sector partners including Howden ($50B AUM), and Ultra PCS (UK MoD supplier). Its platform is designed to integrate seamlessly with Identity and Access Management (IAM) systems such as Okta and to embed directly into wearables—ranging from military helmets to medical headbands.

This investment builds on GenLab’s broader strategy: accelerating AI-native infrastructure where identity integrity, system trust, and geopolitical resilience converge.  

Media Contact: [email protected]

About GenLab

GenLab is a San Francisco–based venture studio building AI-native companies to secure and empower the future of infrastructure, autonomy, and global resilience.

About Lymbic AI

Lymbic AI develops Neuroprint—a privacy-preserving biometric authentication system based on EEG brainwave patterns. Its platform delivers continuous, spoof-resistant authentication for high-security environments, integrating seamlessly into wearable devices and enterprise IAM systems.
[email protected]